A Swiss Microbiota biotherapeutics and Vaccines company, a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: 1. ApyraVax® with the lead indication of Clostridium difficile infection 2. ApyraMed® with lead indications as enhancer in cancer immunotherapy and modulator of antibiotic-induced disbyosis. Research experiments and preclinical trials are performed in the research lab hosted at IRB.  The company is looking for seed funding in order to move forward as a fully operational company into clinics with the main indications.